Gold prices steady, holding sharp gains in wake of soft U.S. jobs data
Investing.com -- NextCure Inc (NASDAQ:NXTC) stock jumped 14% following the presentation of promising preclinical data for its novel anti-Siglec-15 antibody, NC605, as a potential treatment for osteogenesis imperfecta (OI), commonly known as brittle bone disease.
The clinical-stage biopharmaceutical company revealed that NC605 demonstrated improved bone microarchitecture and reduced fracture incidence compared to anti-sclerostin treatment in a well-established OI model. The data was presented at the Brittle Bone Society Meeting on July 24th, 2025.
In the study, male and female OI mice treated with NP159, the murine antibody parent to NC605, showed increased cortical and trabecular bone mineral density, improved tissue mineral density, and enhanced cortical thickness compared to saline-treated mice.
"In a mouse model of moderate-to-severe OI, NP159, a surrogate murine antibody for NC605, improved trabecular and cortical bone density and reduced fracture incidence comparable to anti-sclerostin," said Priyanka Kothari, NextCure’s Director of Translational Research.
The research was conducted in collaboration with Dr. Cathleen Raggio from Hospital for Special Surgery in New York. Unlike current anti-resorptive treatments that inhibit both bone loss and formation, NC605 reportedly inhibits bone loss while producing new bone with increased quality and density.
NextCure is now seeking financial partners to advance NC605 toward a possible Investigational New Drug submission within the next 12 to 18 months. The company noted that there is currently no FDA-approved standard of care for OI patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.